Theravance Biopharma, Inc. · NASDAQ:TBPH
Theravance Biopharma — Corporate Update (September 2021)
10 slides from Theravance Biopharma's corporate update, Sep 15, 2021
Slide 1: A New, Focused Theravance Biopharma
A New, Focused Theravance Biopharma September 15, 2021 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks use
Slide 2: Forward-looking statements safe harbor
Under the safe harbor provisions of the U . S . Private Securities Litigation Reform Act of 1995 , the company cautions investors that any forward - looking statements or projections made by the company are subject to risks and uncertainties that may cause actual results to differ materially from th
Slide 3: A new, focused Theravance Biopharma
A new, focused Theravance Biopharma 1. Excludes share - based compensation and any one - time costs related to strategic action. 2. Source: Bloomberg Consensus Sept 2021. COPD, chronic obstructive pulmonary disease; JAK, Janus kinase; PIFR, peak inspiratory flow rate. 3 ‣ Significant cost reduction
Slide 4: Key pillars focus on immediate sustainable value creation
Key pillars focus on immediate sustainable value creation 1. Source: Bloomberg Consensus Sept 2021. 2. Source: TBPH Broker Consensus Sept 2021. 2. JAK, Janus kinase; PIFR, peak inspiratory flow rate. 4 TRELEGY YUPELRI ® Potential Upside From Core Respiratory Pipeline ‣ Estimated global peak sales of
Slide 5: Significant OPEX reduction to drive sustainable profitability beginning in 2H 2022
$230 $210 $185 $60 $82 $85 $80 $35 2020A 2021 Guidance 2021 Guidance (Revised) 2022 Guidance R&D SG&A Significant OPEX reduction to drive sustainable profitability beginning in 2H 2022 1. Represents mid - point of guidance range. 2. Excluding share - based compensation and any one - time costs relat
Slide 6: Pipeline focused on core respiratory opportunities
Pipeline focused on core respiratory opportunities 1. Excluding programs that are in the process of being wound down following restructuring. 2. Excluding share - based compensation and any one - time costs related to strategic actions. JAK, Janus kinase; PIFR, peak inspiratory flow rate. 6 Legacy T
Slide 7: Strong TRELEGY and YUPELRI revenue performance expected to continue
Strong TRELEGY and YUPELRI ® revenue performance expected to continue 1. Source: Bloomberg Consensus Sept 2021. 2. Source: TBPH Broker Consensus Sept 2021. COPD, chronic obstructive pulmonary disease. 7 TRELEGY YUPELRI Q2 2021 net sales of $405M; implies run rate annual sales of ~$1.6B Year - over -
Slide 8: A new, focused Theravance Biopharma
A new, focused Theravance Biopharma 8 ‣ Significant cost reduction program reduces Company size to become sustainably cash - flow positive beginning 2H 2022 ‣ Focus on leveraging expertise in developing and commercializing respiratory therapeutics ‣ R&D investment streamlined to focus on core respir
Slide 9: About YUPELRI (revefenacin) inhalation solution
About YUPELRI ® (revefenacin) inhalation solution YUPELRI ® (revefenacin) inhalation solution is a once - daily nebulized LAMA approved for the maintenance treatment of COPD in the US . Market research by Theravance Biopharma indicates approximately 9 % of the treated COPD patients in the US use neb
Slide 10: YUPELRI (revefenacin) inhalation solution Important Safety Information
YUPELRI ® (revefenacin) inhalation solution YUPELRI ® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) . Important Safety Information (US) YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any co
Theravance Biopharma — Corporate Update (September 2021) on 6ix